Stifel Reiterates Buy on Alnylam Pharmaceuticals, Maintains $240 Price Target
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Paul Matteis has reiterated a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY) and maintained a price target of $240.
September 14, 2023 | 2:14 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst maintains a 'Buy' rating on Alnylam Pharmaceuticals with a price target of $240.
The reiteration of a 'Buy' rating by a Stifel analyst indicates a positive outlook for Alnylam Pharmaceuticals. The maintained price target of $240 suggests that the analyst believes the stock has potential for significant growth. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100